曲妥珠单抗德鲁替康治疗经血浆游离DNA检测识别的人表皮生长因子受体2扩增晚期实体瘤:一项多中心、单臂、II期篮式试验
HERALD/EPOC1806是一项多中心单臂II期篮式试验,评估曲妥珠单抗德鲁替康(T-DXd)对经游离DNA(cfDNA)检测发现人表皮生长因子受体2(HER2)扩增的晚期实体瘤患者的疗效。研究纳入62例16种癌症类型的患者,T-DXd 5.4 mg/kg每3周一次给药,确认的客观缓解率(ORR)为56.5%(95%CI 43.3-69.0),中位无进展生存期7.0个月,中位缓解持续时间8.8个月,间质性肺病发生16例(26%)。结论认为T-DXd在此类患者中显示高ORR和持久缓解。
要点
- 经cfDNA检测HER2扩增的晚期实体瘤患者接受T-DXd 5.4 mg/kg每3周一次,确认ORR为56.5%(95%CI 43.3-69.0)。
- 中位无进展生存期7.0个月(95%CI 4.9-9.7),中位缓解持续时间8.8个月(95%CI 5.8-11.2)。
- 间质性肺病发生16例(26%),其中1级14例、2级1例、3级1例。
核心结论
- T-DXd治疗在经cfDNA检测确定的晚期HER2扩增实体瘤患者中显示出高ORR和持久缓解。
研究设计与样本
- HERALD/EPOC1806为多中心、单臂、II期篮式试验,评估T-DXd对经cfDNA检测发现HER2扩增的晚期实体瘤患者的疗效。
- 患者无需免疫组化HER2检测,经下一代测序cfDNA检测确认HER2扩增。
- 研究组接受T-DXd 5.4 mg/kg每3周一次,直至疾病进展或不可耐受毒性。
主要发现
- 2019年12月至2022年1月共4734例患者接受cfDNA检测,252例显示HER2扩增,最终纳入62例16种癌症类型患者,中位基线血浆HER2拷贝数(CN)为8.55(范围2.4-73.9)。
- 研究者评估的确认ORR为56.5%(95%CI 43.3-69.0),超过5%阈值。
- 缓解在13种癌症类型中评估,包括KRAS突变结直肠癌(1/3)、PIK3CA突变子宫内膜癌(5/6)和组织HER2阴性胃癌(1/2)。
- 基线血浆HER2 CN高于与低于中位值对缓解影响无差异;第2周期第1天cfDNA中HER2扩增清除者缓解值高于持续存在者。
- 中位无进展生存期和缓解持续时间分别为7.0个月(95%CI 4.9-9.7)和8.8个月(95%CI 5.8-11.2),多数并发症为轻至中度。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: HERALD/EPOC1806 was conducted as a multicenter phase II trial assessing trastuzumab deruxtecan (T-DXd) therapy for patients with human epidermal growth factor receptor 2 (HER2)-amplified progressive stage solid tumors detected by cell-free DNA (cfDNA) testing. PATIENTS AND METHODS: Patients exhibited advanced solid tumors with HER2 amplification that was identified via next-generation sequencing of cfDNA testing, without the requirement for immunohistochemical HER2 testing. The studied group was administered T-DXd at 5.4 mg/kg once every 3 weeks until onset of disease progression or intolerable toxicity. RESULTS: Overall, 4,734 patients underwent cfDNA testing from December 2019 to January 2022, and 252 demonstrated HER2 amplification. Finally, the study included 62 patients with 16 cancer types with a median baseline plasma HER2 copy number (CN) of 8.55 (range, 2.4-73.9). Confirmed overall response rate (ORR) by investigator assessment was 56.5% (95% CI, 43.3 to 69.0), thus showing a value beyond the 5% threshold. Responses were evaluated for 13 cancer types, including KRAS-mutant colorectal (1/3), PIK3CA-mutant endometrial (5/6), and tissue HER2-negative gastric (1/2) cancers. Plasma HER2 CN above versus below the baseline median value did not differ for impact response; however, clearance of HER2 amplification in cfDNA on cycle 2 day 1 had higher response values compared with persistence. Median progression-free survival and response duration were 7.0 (95% CI, 4.9 to 9.7) and 8.8 (95% CI, 5.8 to 11.2) months, respectively, with the majority of complications being mild to moderate. Interstitial lung diseases were identified in 16 (26%) patients, including 14 patients with grade 1 disease, one patient with grade 2 disease, and one patient with grade 3 disease. CONCLUSION: T-DXd treatment demonstrated high ORR with durable response in patients with advanced HER2-amplified solid tumors determined with cfDNA testing.
引用
- Yagisawa M, Taniguchi H, Satoh T, et al. Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial. J Clin Oncol. 2024. PMID: 39088783. doi:10.1200/JCO.23.02626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。